Prot #B1371003: A Phase 1B Study to Evaluate the Safety and Preliminary Efficacy of PF-04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive Chemotherapy, Low Dose ARA-C or Decitabine in Patients with Acute Myeloid Leukemia or High-Risk Myel

Project: Research project

Project Details

StatusFinished
Effective start/end date10/17/12 → 10/17/18

Funding

  • ICON Clinical Research, LLC (Prot #B1371003 // Prot #B1371003)
  • Pfizer Inc. (Prot #B1371003 // Prot #B1371003)